|Description||CBB1007, an amidino-guanidinium derivative, has been found to have biological activity in anticancer-study by acting as a LSD1 inhibitor. IC50: 5.27 uM.|
|Synonyms||CBB1007; SCHEMBL16273312; CS-1737|
|Solubility||10 mM in DMSO|
|Application||CBB1007 has been found to have biological activity in anticancer-study by acting as a LSD1 inhibitor.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just ...
NL-103, a nicotinamide derivative, has been found to be an inhibitor of both histone deacetylases and hedgehog pathway. It was found to exhibit activity in decr...
CBB1003, a piperazine derivative, has been found to be a histone demethylase LSD1 inhibitor that could restrain the proliferation and colony formation of CRC ce...
CPI 4203 is a selective inhibitor of KDM5 demethylases structurally related to CPI 455.
DDP-38003 trihydrochloride is the trihydrochloride salt of DDP-38003 which is a potent, selective, oral bioavailable irreversible inhibitor of KDM1A.
KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).
(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth vi...
SP2509 inhibits the association of LSD1 with CoREST, increases promoter-specific H3K4Me3 and induces p53, p21 and C/EBPα. SP2509 also significantly inhibits the...